Pooled analysis of 5 RCTs of tocilizumab vs DMARDs in 4474 female #RA pts- 63% postmenopausal, 23% premenopausal, 9% perimenopausal. Perimenopausal F had less remission (HR 0.78); but exogenous Sex hormone use had higher remission (HR 1.20) https://t.co/zmvpzFlBRQ https://t.co/lUbGKr4akR